A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy.
T-cell retargeting
TRAIL-R2
bispecific antibody
immunotherapy
malignant ascites
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
05
2019
accepted:
08
10
2019
entrez:
12
11
2019
pubmed:
12
11
2019
medline:
3
11
2020
Statut:
epublish
Résumé
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymphocytes toward cancer cells by bispecific antibodies (bsAbs) that engage the CD3 complex and a tumor-associated antigen (TAA). The TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) is an attractive immunotherapy target, frequently expressed by neoplastic cells, that we decided to exploit as a TAA. We found that a TRAIL-R2xCD3 bsAb efficiently activates T cells and specifically redirect their cytotoxicity against cancer cells of different origins
Identifiants
pubmed: 31708930
doi: 10.3389/fimmu.2019.02514
pmc: PMC6823250
doi:
Substances chimiques
Antibodies, Bispecific
0
Antigens, Neoplasm
0
CD3 Complex
0
Receptors, TNF-Related Apoptosis-Inducing Ligand
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2514Informations de copyright
Copyright © 2019 Satta, Grazia, Caroli, Frigerio, Di Nicola, Raspagliesi, Mezzanzanica, Zaffaroni, Gianni, Anichini and Figini.
Références
Nat Rev Cancer. 2002 Jun;2(6):420-30
pubmed: 12189384
Trends Pharmacol Sci. 2014 Oct;35(10):520-36
pubmed: 25128958
Am J Cancer Res. 2012;2(1):75-92
pubmed: 22206047
Int J Cancer. 1985 Sep 15;36(3):337-43
pubmed: 3875569
Arch Gynecol Obstet. 2013 Sep;288(3):581-5
pubmed: 23644922
Ann Oncol. 2007 May;18(5):945-9
pubmed: 17298959
Cell Death Dis. 2014 Oct 02;5:e1434
pubmed: 25275595
Cell Death Differ. 2003 Jan;10(1):66-75
pubmed: 12655296
Drugs. 2015 Feb;75(3):321-7
pubmed: 25637301
J Clin Invest. 2008 Jun;118(6):1979-90
pubmed: 18523647
J Clin Invest. 1999 Jul;104(2):155-62
pubmed: 10411544
Nat Med. 1999 Feb;5(2):157-63
pubmed: 9930862
Cancer Cell. 2017 Mar 13;31(3):383-395
pubmed: 28262555
Biochem Biophys Res Commun. 2000 Feb 16;268(2):398-404
pubmed: 10679216
Cancer Res. 2004 Oct 15;64(20):7386-94
pubmed: 15492260
Cell. 2017 Feb 9;168(4):724-740
pubmed: 28187291
Future Oncol. 2013 Apr;9(4):527-39
pubmed: 23560375
Nat Rev Cancer. 2008 Oct;8(10):782-98
pubmed: 18813321
Cell Res. 2005 Jun;15(6):430-8
pubmed: 15987601
Exp Biol Med (Maywood). 2015 Jun;240(6):760-73
pubmed: 25854879
Drug Discov Today. 2015 Jul;20(7):838-47
pubmed: 25728220
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Immunol Methods. 1994 Jun 24;172(2):227-39
pubmed: 7518485
J Microsc. 2006 Dec;224(Pt 3):213-32
pubmed: 17210054
Int J Cancer. 2010 Nov 1;127(9):2209-21
pubmed: 20473913
Cancer Cell. 2017 Mar 13;31(3):396-410
pubmed: 28262554
Eur J Immunol. 1987 Jan;17(1):105-11
pubmed: 3102250
Nat Rev Cancer. 2017 May 24;17(6):352-366
pubmed: 28536452
Int J Gynecol Pathol. 2012 May;31(3):211-21
pubmed: 22498937
Cancer Res. 2010 Nov 1;70(21):8378-87
pubmed: 20861189
MAbs. 2018 Oct;10(7):1084-1097
pubmed: 29993310